• Something wrong with this record ?

Effect of Cellular and Microenvironmental Multidrug Resistance on Tumor-Targeted Drug Delivery in Triple-Negative Breast cancer

O. Tezcan, AS. Elshafei, K. Benderski, E. Rama, M. Wagner, D. Moeckel, R. Pola, M. Pechar, T. Etrych, S. von Stillfried, F. Kiessling, R. Weiskirchen, S. Meurer, T. Lammers

. 2023 ; 354 (-) : 784-793. [pub] 20230128

Language English Country Netherlands

Document type Journal Article, Research Support, Non-U.S. Gov't

Multidrug resistance (MDR) reduces the efficacy of chemotherapy. Besides inducing the expression of drug efflux pumps, chemotherapy treatment alters the composition of the tumor microenvironment (TME), thereby potentially limiting tumor-directed drug delivery. To study the impact of MDR signaling in cancer cells on TME remodeling and nanomedicine delivery, we generated multidrug-resistant 4T1 triple-negative breast cancer (TNBC) cells by exposing sensitive 4T1 cells to gradually increasing doxorubicin concentrations. In 2D and 3D cell cultures, resistant 4T1 cells are presented with a more mesenchymal phenotype and produced increased amounts of collagen. While sensitive and resistant 4T1 cells showed similar tumor growth kinetics in vivo, the TME of resistant tumors was enriched in collagen and fibronectin. Vascular perfusion was also significantly increased. Fluorophore-labeled polymeric (∼10 nm) and liposomal (∼100 nm) drug carriers were administered to mice with resistant and sensitive tumors. Their tumor accumulation and penetration were studied using multimodal and multiscale optical imaging. At the whole tumor level, polymers accumulate more efficiently in resistant than in sensitive tumors. For liposomes, the trend was similar, but the differences in tumor accumulation were insignificant. At the individual blood vessel level, both polymers and liposomes were less able to extravasate out of the vasculature and penetrate the interstitium in resistant tumors. In a final in vivo efficacy study, we observed a stronger inhibitory effect of cellular and microenvironmental MDR on liposomal doxorubicin performance than free doxorubicin. These results exemplify that besides classical cellular MDR, microenvironmental drug resistance features should be considered when aiming to target and treat multidrug-resistant tumors more efficiently.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004317
003      
CZ-PrNML
005      
20230425141302.0
007      
ta
008      
230418s2023 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jconrel.2022.12.056 $2 doi
035    __
$a (PubMed)36599395
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Tezcan, Okan $u Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, University Hospital RWTH Aachen, Aachen, Germany.; UT Brown Foundation Institute of Molecular Medicine, UTHealth Houston, Houston, TX, USA. Electronic address: okan.tezcan@uth.tmc.edu
245    10
$a Effect of Cellular and Microenvironmental Multidrug Resistance on Tumor-Targeted Drug Delivery in Triple-Negative Breast cancer / $c O. Tezcan, AS. Elshafei, K. Benderski, E. Rama, M. Wagner, D. Moeckel, R. Pola, M. Pechar, T. Etrych, S. von Stillfried, F. Kiessling, R. Weiskirchen, S. Meurer, T. Lammers
520    9_
$a Multidrug resistance (MDR) reduces the efficacy of chemotherapy. Besides inducing the expression of drug efflux pumps, chemotherapy treatment alters the composition of the tumor microenvironment (TME), thereby potentially limiting tumor-directed drug delivery. To study the impact of MDR signaling in cancer cells on TME remodeling and nanomedicine delivery, we generated multidrug-resistant 4T1 triple-negative breast cancer (TNBC) cells by exposing sensitive 4T1 cells to gradually increasing doxorubicin concentrations. In 2D and 3D cell cultures, resistant 4T1 cells are presented with a more mesenchymal phenotype and produced increased amounts of collagen. While sensitive and resistant 4T1 cells showed similar tumor growth kinetics in vivo, the TME of resistant tumors was enriched in collagen and fibronectin. Vascular perfusion was also significantly increased. Fluorophore-labeled polymeric (∼10 nm) and liposomal (∼100 nm) drug carriers were administered to mice with resistant and sensitive tumors. Their tumor accumulation and penetration were studied using multimodal and multiscale optical imaging. At the whole tumor level, polymers accumulate more efficiently in resistant than in sensitive tumors. For liposomes, the trend was similar, but the differences in tumor accumulation were insignificant. At the individual blood vessel level, both polymers and liposomes were less able to extravasate out of the vasculature and penetrate the interstitium in resistant tumors. In a final in vivo efficacy study, we observed a stronger inhibitory effect of cellular and microenvironmental MDR on liposomal doxorubicin performance than free doxorubicin. These results exemplify that besides classical cellular MDR, microenvironmental drug resistance features should be considered when aiming to target and treat multidrug-resistant tumors more efficiently.
650    _2
$a lidé $7 D006801
650    _2
$a zvířata $7 D000818
650    _2
$a myši $7 D051379
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a liposomy $7 D008081
650    12
$a triple-negativní karcinom prsu $7 D064726
650    _2
$a chemorezistence $7 D019008
650    _2
$a doxorubicin $7 D004317
650    _2
$a mnohočetná léková rezistence $7 D018432
650    _2
$a polymery $x farmakologie $7 D011108
650    _2
$a nádorové buněčné linie $7 D045744
650    12
$a nádory prsu $7 D001943
650    _2
$a nádorové mikroprostředí $7 D059016
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Elshafei, Asmaa Said $u Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, University Hospital RWTH Aachen, Aachen, Germany
700    1_
$a Benderski, Karina $u Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, University Hospital RWTH Aachen, Aachen, Germany
700    1_
$a Rama, Elena $u Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, University Hospital RWTH Aachen, Aachen, Germany
700    1_
$a Wagner, Maike $u Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, University Hospital RWTH Aachen, Aachen, Germany
700    1_
$a Moeckel, Diana $u Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, University Hospital RWTH Aachen, Aachen, Germany
700    1_
$a Pola, Robert $u Institute of Macromolecular Chemistry, Czech Academy of Science, Prague, Czech Republic
700    1_
$a Pechar, Michal $u Institute of Macromolecular Chemistry, Czech Academy of Science, Prague, Czech Republic
700    1_
$a Etrych, Tomas $u Institute of Macromolecular Chemistry, Czech Academy of Science, Prague, Czech Republic
700    1_
$a von Stillfried, Saskia $u Institute of Pathology, University Hospital RWTH Aachen, Aachen, Germany; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University Hospital RWTH Aachen, Aachen, Germany
700    1_
$a Kiessling, Fabian $u Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, University Hospital RWTH Aachen, Aachen, Germany
700    1_
$a Weiskirchen, Ralf $u Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), University Hospital RWTH Aachen, Aachen, Germany
700    1_
$a Meurer, Steffen $u Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), University Hospital RWTH Aachen, Aachen, Germany
700    1_
$a Lammers, Twan $u Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, University Hospital RWTH Aachen, Aachen, Germany.. Electronic address: tlammers@ukaachen.de
773    0_
$w MED00002621 $t Journal of controlled release : official journal of the Controlled Release Society $x 1873-4995 $g Roč. 354, č. - (2023), s. 784-793
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36599395 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425141258 $b ABA008
999    __
$a ok $b bmc $g 1924787 $s 1190526
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 354 $c - $d 784-793 $e 20230128 $i 1873-4995 $m Journal of controlled release $n J Controlled Release $x MED00002621
LZP    __
$a Pubmed-20230418

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...